Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Release time:
2026-01-04
On the afternoon of December 30th, the "Innovation, Entrepreneurship, and Shared Future" 2025 Jinan Achievements Conference was successfully held at the Qilu Science and Technology Finance Building. Organized by the Municipal Science and Technology Bureau, Municipal Party Committee Organization Department, Municipal Party Committee Financial Office, Municipal Development and Reform Commission, Municipal Industry and Information Technology Bureau, Municipal Bureau for Private Economy, and the Lixia District Government, the conference aimed to thoroughly implement the innovation-driven development strategy, accelerate the construction of a full-process innovation ecosystem, focus on the transformation of scientific and technological achievements, and promote the "Jinan Achievements" brand. Among the numerous achievements presented, the globally first-of-its-kind ovarian tissue dual activation technology developed by Shandong Yinfeng Life Science Research Institute made a significant debut, offering new hope for addressing fertility challenges.
Authorities Gather to Build an Innovation Ecosystem
Attending and delivering speeches were leaders including Yu Hongwen, Party Leadership Group Member and Deputy Director of the Shandong Provincial Department of Science and Technology; Xie Kun, Vice Mayor of Jinan Municipal People's Government; and Wang Lijun, Director of the Information Theory and Methodology Research Center of the China Science and Technology Information Institute directly under the Ministry of Science and Technology. They emphasized that Jinan is actively accelerating the construction of a full-process innovation ecosystem encompassing "basic research + technological breakthroughs + achievement industrialization + sci-tech finance + talent support" to promote the deep integration of technological innovation with economic and social development. At the conference, the "Jinan Sci-Tech Brain" and the Jinan Sci-Tech Achievement Transformation AI Large Model Platform were officially launched, providing powerful intelligent support for transforming scientific and technological achievements. Simultaneously, the conference unveiled the "Jinan Achievements" list and awarded the winning teams.
A Global First, Tackling Fertility Challenges
As one of the Jinan achievements, Shandong Yinfeng Life Science Research Institute showcased its globally pioneering ovarian tissue dual activation technology at this conference. In June 2025, this technology successfully helped a patient with premature ovarian insufficiency achieve natural conception and a smooth delivery, providing a novel solution for infertility, diminished ovarian reserve, and fertility preservation for cancer patients of reproductive age.
Premature ovarian failure refers to the decline of ovarian function in women before the age of 40. China sees about 1.4 million new patients annually. Severe premature ovarian failure is termed "reproductive cancer," with no effective clinical treatment currently available. To tackle this challenge, Shandong Yinfeng Life Science Research Institute, in collaboration with Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, innovatively combined in vitro vitrification cryoactivation technology for ovarian tissue with autologous venous plasma-derived cytokine (PFC) activation technology, offering a new solution for infertility, diminished ovarian reserve, and fertility preservation for cancer patients of reproductive age.
Original Technology with Distinct Advantages
The R&D team successively overcame core technologies including ice inhibition, balanced vitrification cryopreservation and rapid uniform rewarming, and extraction and lyophilization of endogenous factors. They successfully developed an ovarian tissue cryoprotectant, a lyophilized preparation of autologous venous plasma-derived cytokines (PFC), and an automated control program for rapid, uniform cooling/rewarming. By innovatively integrating the IVA (In Vitro Activation) technology with the PFC technology, they created the world's first ovarian tissue dual activation technology.
This activation procedure involves physical intervention, does not rely on drugs or hormones, and achieves a natural conception rate approximately 20 times higher than other related treatment technologies.
Future Outlook: Contributing to a Fertility-Friendly Society
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
Previous article
Latest developments
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
According to the latest announcement from the International Society of Cryobiology, Professor Xu Yi from the School of Health Science and Engineering at the University of Shanghai for Science and Technology, and a member of the Yinfeng Cryomedicine Expert Committee, has been elected as a Board Governor of the Society for a three-year term (2026–2028). The election was conducted through a democratic vote by all members worldwide, with three new Board Governors elected. Professor Xu Yi is the only scholar from Asia elected to the Society’s Board of Governors this time and the third elected scholar from mainland China in the Society’s 60-year history.
The significance of life extension lies not only in technological breakthroughs but also in the shared belief of every individual who believes in "a better future." With faith as their torch, these fellow travelers join hands, pooling their strength to stride forward together. We firmly believe that as this steadfast support converges into a powerful force, it will propel the Yinfeng Life Extension Plan to gain broader attention, inject continuous momentum into the development of cryobiomedicine, and illuminate the next chapter of human civilization.
Over the two days, the symposium was not only a collision of ideas but also seeds sown to advance social progress in life culture. The Shandong Yinfeng Life Science Public Welfare Foundation will continue to use technology as wings and culture as roots, collaborating with all sectors of society to enhance the quality of life for the Chinese people and build a human-centered life care system.
According to recent announcements by the Jinan Municipal Bureau of Science and Technology, 11 outstanding achievements from Jinan have been included in the 2025 "Shandong Outstanding Achievements Report" project. Among them is the globally first-of-its-kind ovarian tissue dual-activation technology developed by Shandong Silver Med Life Science Research Institute (Jinan).
Recently, Frigid Zone Medicine, an authoritative international journal in the field of cryomedicine, published an important review titled "Advances in the Detection Methods for Assessing the Viability of Cryopreserved Samples". Written by the team of Yinfeng Cryomedical Research Center, the article systematically reviews and analyzes various detection techniques currently used to evaluate the viability of cryopreserved cells, tissues, and organs. It also proposes key directions from the perspectives of methodological integration and future instrument development, offering crucial theoretical support and practical guidance for the long - term cryopreservation of complex tissues and organs.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155507
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
